Full Text View
Tabular View
No Study Results Posted
Related Studies
SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients (STARLYTE)
This study is currently recruiting participants.
Verified April 2013 by Sanofi
Study NCT01472887   Information provided by Sanofi

First Received on November 14, 2011.   Last Updated on April 18, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Diffuse Large B-cell Lymphoma
Additional conditions recognized in this trial
Lymphoma
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
SAR3419
Sponsors listed in this trial
Sanofi


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services